Investigational drug · Phase 2
VHB937
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "VHB937"
First trial start
2024
Oct 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VHB937", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis (ALS)
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "VHB937" as an intervention, largest first.
- A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06643481 · 251 participants · Start Oct 17, 2024 · Primary completion Jun 23, 2026
Drug: VHB937 · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: La Jolla, California; Loma Linda, California; Los Angeles, California · 74 sites in all
- A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseaseActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07094516 · 96 participants · Start Aug 7, 2025 · Primary completion Sep 14, 2028
Drug: VHB937; VHB937 · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 73 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Amyotrophic Lateral Sclerosis (ALS)
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- COYA 302Phase 31 trial
Coya Therapeutics · Amyotrophic Lateral Sclerosis (ALS)
- ALT001Phase 22 trials
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS)
- FHND1002Phase 21 trial
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
- NB-4746Phase 21 trial
Nura Bio · Amyotrophic Lateral Sclerosis (ALS)
- SNUG01Phase 21 trial
SineuGene Therapeutics Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.